Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Provided By GlobeNewswire
Last update: May 12, 2025
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission
